Linking the future of anticancer metal-complexes to the therapy of tumour metastases
Cancer chemotherapy is almost always applied to patients with one or more diagnosed metastases and is expected to impact these lesions, thus providing significant benefits to the patient. The outcome of metastasis is determined by the interplay between the specific subpopulation of metastatic cells...
Saved in:
| Published in | Chemical Society reviews Vol. 44; no. 24; pp. 8818 - 8835 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
England
21.12.2015
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Summary: | Cancer chemotherapy is almost always applied to patients with one or more diagnosed metastases and is expected to impact these lesions, thus providing significant benefits to the patient. The outcome of metastasis is determined by the interplay between the specific subpopulation of metastatic cells and host homeostatic factors in specific microenvironments. In clinical practice, metal-based drugs are represented by platinum compounds, which are constituents of a wide variety of chemotherapeutic regimens, and are only rarely active against tumour metastases unless they are combined with drugs that target specific pathways characterizing the malignancy of the tested tumour. On experimental grounds, a number of complexes based on ruthenium and other metals have been frequently studied
in vitro
using models and experimental conditions mimicking one or more steps of the metastatic process, such as invasion and migration. The ruthenium-based drug, NAMI-A, is the only one to have been subject to clinical testing for the treatment of metastatic tumours. The capacity of NAMI-A to modulate the relationship established between metastatic cells and their microenvironment suggests that metal-based drugs shall be viewed as an opportunity for the treatment of tumour metastases.
Cancer chemotherapy is almost always applied to patients with one or more diagnosed metastases and is expected to impact these lesions, thus providing significant benefits to the patient. |
|---|---|
| Bibliography: | Dr Alberta Bergamo is a Researcher at the Callerio Foundation Onlus, a private non-profit research institute, where she works in the field of Medicinal Inorganic Chemistry focusing on the study of metallodrugs against solid tumour metastases and tumour microenvironments. Prof. Gianni Sava is Professor of Pharmacology at the University of Trieste. He has a long lasting expertise in the pre-clinical pharmacological study of chemicals for the control of the formation and growth of tumour metastases. He has co-authored 260 full length papers mainly focusing on metal-based compounds and he is responsible for the pharmacological development of the ruthenium-based antitumour drug NAMI-A. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ISSN: | 0306-0012 1460-4744 1460-4744 |
| DOI: | 10.1039/c5cs00134j |